Getting drugs to where they are needed: Global public private partnerships for neglected diseases

To an increasing extend the research, development and delivery of drugs for neglected diseases is undertaken by Public Private Partnerships. Concerns are being raised about their key characteristics, like the inequality of the partners or their relationship with international organizations. This article analyses the impacts at country level, such as additional cost and workload through one-to-one negotiations between the initiatives and the countries, to the demands on the existing health systems. It also assesses the increasing inequalities within and between countries.